Selected research
Market Structure
Global Bevacizumab Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Bevacizumab market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Bevacizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Bevacizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Bevacizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Bevacizumab is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Bevacizumab include Mylan, Genentech, Amgen, MVASI (bevacizumab), Beacon Pharmaceuticals Limited, Balaji Medical Services Private Limited and Aark Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Bevacizumab market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Bevacizumab and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Bevacizumab sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Bevacizumab market size, projected growth trends, production technologies, key applications, and end-use industries.
Bevacizumab Segment by Company
Mylan
Genentech
Amgen
MVASI (bevacizumab)
Beacon Pharmaceuticals Limited
Balaji Medical Services Private Limited
Aark Pharmaceuticals
Bevacizumab Segment by Type
Avastin (bevacizumab)
Mvasi (bevacizumab-awwb)
Bevacizumab Segment by Application
Cancer
Eye Diease
Bevacizumab Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Bevacizumab market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bevacizumab manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bevacizumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Bevacizumab in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Avastin (bevacizumab)
- Mvasi (bevacizumab-awwb)
Applications
- Cancer
- Eye Diease
Companies covered
- Mylan
- Genentech
- Amgen
- MVASI (bevacizumab)
- Beacon Pharmaceuticals Limited
- Balaji Medical Services Private Limited
- Aark Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Bevacizumab Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Bevacizumab Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Bevacizumab Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Bevacizumab Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Bevacizumab Market Dynamics
- 2.1 Bevacizumab Industry Trends
- 2.2 Bevacizumab Industry Drivers
- 2.3 Bevacizumab Industry Opportunities and Challenges
- 2.4 Bevacizumab Industry Restraints
3 Bevacizumab Market by Manufacturers
- 3.1 Global Bevacizumab Revenue by Manufacturers (2021-2026)
- 3.2 Global Bevacizumab Sales by Manufacturers (2021-2026)
- 3.3 Global Bevacizumab Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Bevacizumab Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Bevacizumab Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Bevacizumab Manufacturers, Product Type & Application
- 3.7 Global Bevacizumab Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Bevacizumab Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Bevacizumab Players Market Share by Revenue in 2025
- 3.8.3 2025 Bevacizumab Tier 1, Tier 2, and Tier 3
4 Bevacizumab Market by Type
- 4.1 Bevacizumab Type Introduction
- 4.1.1 Avastin (bevacizumab)
- 4.1.2 Mvasi (bevacizumab-awwb)
- 4.2 Global Bevacizumab Sales by Type
- 4.2.1 Global Bevacizumab Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Bevacizumab Sales by Type (2021-2032)
- 4.2.3 Global Bevacizumab Sales Market Share by Type (2021-2032)
- 4.3 Global Bevacizumab Revenue by Type
- 4.3.1 Global Bevacizumab Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Bevacizumab Revenue by Type (2021-2032)
- 4.3.3 Global Bevacizumab Revenue Market Share by Type (2021-2032)
5 Bevacizumab Market by Application
- 5.1 Bevacizumab Application Introduction
- 5.1.1 Cancer
- 5.1.2 Eye Diease
- 5.2 Global Bevacizumab Sales by Application
- 5.2.1 Global Bevacizumab Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Bevacizumab Sales by Application (2021-2032)
- 5.2.3 Global Bevacizumab Sales Market Share by Application (2021-2032)
- 5.3 Global Bevacizumab Revenue by Application
- 5.3.1 Global Bevacizumab Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Bevacizumab Revenue by Application (2021-2032)
- 5.3.3 Global Bevacizumab Revenue Market Share by Application (2021-2032)
6 Global Bevacizumab Sales by Region
- 6.1 Global Bevacizumab Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Bevacizumab Sales by Region (2021-2032)
- 6.2.1 Global Bevacizumab Sales by Region (2021-2026)
- 6.2.2 Global Bevacizumab Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Bevacizumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Bevacizumab Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Bevacizumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Bevacizumab Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Bevacizumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Bevacizumab Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Bevacizumab Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Bevacizumab Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Bevacizumab Revenue by Region
- 7.1 Global Bevacizumab Revenue by Region
- 7.1.1 Global Bevacizumab Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Bevacizumab Revenue by Region (2021-2026)
- 7.1.3 Global Bevacizumab Revenue by Region (2027-2032)
- 7.1.4 Global Bevacizumab Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Bevacizumab Revenue (2021-2032)
- 7.2.2 North America Bevacizumab Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Bevacizumab Revenue (2021-2032)
- 7.3.2 Europe Bevacizumab Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Bevacizumab Revenue (2021-2032)
- 7.4.2 Asia-Pacific Bevacizumab Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Bevacizumab Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Bevacizumab Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Mylan
- 8.1.1 Mylan Company Information
- 8.1.2 Mylan Business Overview
- 8.1.3 Mylan Bevacizumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Mylan Bevacizumab Product Portfolio
- 8.1.5 Mylan Recent Developments
- 8.2 Genentech
- 8.2.1 Genentech Company Information
- 8.2.2 Genentech Business Overview
- 8.2.3 Genentech Bevacizumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Genentech Bevacizumab Product Portfolio
- 8.2.5 Genentech Recent Developments
- 8.3 Amgen
- 8.3.1 Amgen Company Information
- 8.3.2 Amgen Business Overview
- 8.3.3 Amgen Bevacizumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Amgen Bevacizumab Product Portfolio
- 8.3.5 Amgen Recent Developments
- 8.4 MVASI (bevacizumab)
- 8.4.1 MVASI (bevacizumab) Company Information
- 8.4.2 MVASI (bevacizumab) Business Overview
- 8.4.3 MVASI (bevacizumab) Bevacizumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 MVASI (bevacizumab) Bevacizumab Product Portfolio
- 8.4.5 MVASI (bevacizumab) Recent Developments
- 8.5 Beacon Pharmaceuticals Limited
- 8.5.1 Beacon Pharmaceuticals Limited Company Information
- 8.5.2 Beacon Pharmaceuticals Limited Business Overview
- 8.5.3 Beacon Pharmaceuticals Limited Bevacizumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Beacon Pharmaceuticals Limited Bevacizumab Product Portfolio
- 8.5.5 Beacon Pharmaceuticals Limited Recent Developments
- 8.6 Balaji Medical Services Private Limited
- 8.6.1 Balaji Medical Services Private Limited Company Information
- 8.6.2 Balaji Medical Services Private Limited Business Overview
- 8.6.3 Balaji Medical Services Private Limited Bevacizumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Balaji Medical Services Private Limited Bevacizumab Product Portfolio
- 8.6.5 Balaji Medical Services Private Limited Recent Developments
- 8.7 Aark Pharmaceuticals
- 8.7.1 Aark Pharmaceuticals Company Information
- 8.7.2 Aark Pharmaceuticals Business Overview
- 8.7.3 Aark Pharmaceuticals Bevacizumab Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Aark Pharmaceuticals Bevacizumab Product Portfolio
- 8.7.5 Aark Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Bevacizumab Value Chain Analysis
- 9.1.1 Bevacizumab Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Bevacizumab Production Mode & Process
- 9.2 Bevacizumab Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Bevacizumab Distributors
- 9.2.3 Bevacizumab Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst